Supplementary Methods

Inclusion criteria
Inclusion criteria were a diagnosis of SS or S beta thalassemia SCD, eligibility for HSCT, the lack of a HLAgenoidentical donor, one or more vaso-occlusive crises (VOCs) in the previous year, two or more episodes of acute thoracic syndrome, joint osteonecrosis, RBC allo-immunization, and/or cardiomyopathy. Apart from the classical causes, non-inclusion criteria included previous allogenic HSCT, major organ failure and granulocyte counts ≥10x10 9 /litre. Eligible patients were identified in the cohort of adult patients with SCD of Necker-Enfants Malades hospital and enrolled consecutively between May 2015 and January 2017. Because of the absence of a direct benefit and the risks incurred by the patients, enrollment was stopped when three SCD patients were analysable and exhibited reproducible results in terms of safety and efficacy. Primary and secondary endpoints were the absence of SAEs and the efficacy of mobilization of HSPCs (defined as ≥20 CD34 + cells/µlitre), respectively.
Apheresis procedure
During the HSPC collection, we noticed that separation of mononuclear cells from granulocytes and red blood cells was not efficient and resulted in an unstable layer of mononuclear cells. This phenomenon has also been observed during the collection of BM mononuclear cells in SCD and in thalassemic patients. 1, 2 In thalassemic patients, this problem was partly solved by collecting mononuclear cells at a deeper layer (toward the RBC layer). 2 Our apheresis procedure was adjusted in the same way (details of the procedure are available upon request). CD34 + cells were further purified by immunomagnetic selection with the CliniMACS System (Miltenyi Biotec, Bergisch Gladbach, Germany) after immunostaining with CliniMACS CD34 Reagent (Miltenyi Biotec). To provide the patients with individual benefit, mobilized CD34 + cells were cryopreserved as a back-up for their inclusion in a subsequent gene therapy trial.
RNA-Seq analysis
The reads were mapped to the human reference genome (hg38) using STAR. Raw gene counts were obtained using featureCounts and GENCODE 25 basic gene annotation. The edgeR R package was used for differential gene expression analysis. Hierarchical cluster analysis was performed using the pvclust R package. Functional enrichment analysis of gene ontology (GO) biological process (BP) categories was performed using the clusterProfiler R package. Gene set enrichment analysis (GSEA) was performed using GSEA software and the Molecular Signature Database (MSigDB). Gene lists for heat map generation were obtained from Lidonnici et al. 3 The datasets supporting the results of this article are available in the Gene Expression Omnibus repository under the accession number GSE102881.
Analysis of engraftment and humanhematopoiesis into non-obese diabetic severe combined immunodeficiency gamma (NSG) mice
Three months after transplantation, the recipients were sacrificed, cells harvested from the femurs, thymus and spleen, stained with antibodies against murine and human markers (Supplementary Table 2 ) and analyzed with flow cytometry using a Gallios analyser and Kaluza software (Beckman Coulter). Human chimerism was calculated according to the following equation: % human CD45 + cells/(% human CD45 + cells + % murine CD45 + cells). For secondary transplantation, 7 to 10 x 10 6 total BM cells (containing around 250,000 human CD34 + cells) were injected into busulfan-conditioned NSG mice, as described above. Analysis was performed three months after transplantation.
Colony Forming Cell (CFC) assay
Plerixafor-mobilized and BM SCD CD34 + cells were plated at 1x10 3 cells/ml in methylcellulose medium supporting the growth of erythroid (BFU-E) and myeloid (CFU-GM) progenitors (GFH4435, Stem Cell Technologies). Before plating, cells were pre-activated for 24 h, as usually performed in our gene therapy protocols, in X-VIVO 20 supplemented with the following recombinant human cytokines (Peprotech): 300 ng/ml SCF, 300 ng/ml Flt-3L, 100 ng/ml TPO and 20 ng/ml IL3. After 14 days, we scored BFU-E and CFU-GM colonies.
In vitro erythroid differentiation
Preactivated, plerixafor-mobilized and BM SCD CD34 + cells were differentiated in mature RBCs using a 3phase protocol adapted from Giarratana et al. 4 From day 0 to day 6, cells were grown in a basal erythroid medium supplemented with the following human recombinant cytokines: 100 ng/mL SCF (Peprotech), 5 ng/mL IL3 (Peprotech), and 3 IU/mL of Epo (Janssen-Cilag), and 10 -6 M hydrocortisone (Sigma). From day 6 to day 9, cells were cultured onto a layer of murine stromal cells (MS-5) in a basal erythroid medium supplemented only with 3 IU/mL Epo. Finally, from day 9 to day 20, cells were cultured onto the MS-5 layer in basal erythroid medium without cytokines. Erythroid differentiation was monitored by May Grunwald-Giemsa staining and FACS analysis of the erythroid surface markers CD36 (CD36-V450, BD Horizon), CD71 (CD71-FITC, BD Pharmingen) and GYPA (CD235a-PECY7, BD Pharmingen) and of the DRAQ5 (eBioscience) nuclear staining using the Gallios FACS analyzer and the Kaluza software (Beckman-Coulter, Brea, CA). 
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